Oral GC Use | Total Fracture | Vertebral Fracture | Hip Fracture |
---|---|---|---|
Duration, mos | |||
0 | Ref | Ref | Ref |
0 and < 3 | 0.99 (0.84–1.17) | 1.15 (0.87–1.51) | 0.57 (0.37–0.89) |
≥ 3 and < 6 | 1.02 (0.84–1.24) | 1.23 (0.89–1.68) | 0.44 (0.24–0.82) |
≥ 6 | 1.30 (1.11–1.52) | 1.80 (1.37–2.36) | 1.21 (0.81–1.81) |
Mean dose, mg/day | |||
0 | Ref | Ref | Ref |
0 and < 2.5 | 1.01 (0.84–1.21) | 1.09 (0.80–1.48) | 0.88 (0.54–1.42) |
≥ 2.5 and < 5 | 1.10 (0.94–1.30) | 1.40 (1.07–1.85) | 0.94 (0.62–1.43) |
≥ 5 and < 7.5 | 1.27 (1.08–1.50) | 1.72 (1.30–2.26) | 1.05 (0.68–1.60) |
≥ 7.5 and < 10 | 1.27 (1.07–1.52) | 1.80 (1.35–2.41) | 0.79 (0.48–1.28) |
≥ 10 | 1.11 (0.93–1.31) | 1.46 (1.10–1.94) | 0.77 (0.49–1.22) |
Highest dose, mg/day | |||
0 | Ref | Ref | Ref |
0 and < 5 | 0.93 (0.75–1.16) | 0.96 (0.66–1.38) | 1.22 (0.72–2.06) |
≥ 5 and < 10 | 1.00 (0.84–1.19) | 1.16 (0.86–1.55) | 0.88 (0.56–1.39) |
≥ 10 and < 20 | 1.17 (1.00–1.37) | 1.53 (1.16–2.00) | 0.88 (0.58–1.32) |
≥ 20 | 1.28 (1.09–1.51) | 1.82 (1.38–2.40) | 0.89 (0.58–1.36) |
Values in bold face indicate statistical significance at the 0.05 level. Each of the variables (duration, mean dose, and highest dose) was adjusted for age, sex, payer type, type of institution, physician specialty, comorbidities (including hyperparathyroidism, hyperthyroidism, ESRD, chronic pulmonary disease, inflammatory bowel disease), and medications related to RA or osteoporosis. Analysis of nonvertebral/nonhip fractures was not performed because of technical limitations in database access. GC: glucocorticoid; RA: rheumatoid arthritis; ESRD: endstage renal disease.